Cerbios header

Cerbios header

X

[{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Leo Pharma"},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Almirall"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eligo Bioscience"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Evommune"},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revel Pharmaceuticals"},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sequence Bio"},{"orgOrder":0,"company":"BiondVax Pharmaceuticals","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiondVax\u2019s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BiondVax Pharmaceuticals"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Concerto Biosciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Concerto Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline

Details:

The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.

Lead Product(s): ENS-002

Therapeutic Area: Dermatology Product Name: ENS-002

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Safar Partners

Deal Size: $23.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing November 02, 2022

ASK
US

Upload
your Pipeline Activity

BiondVax Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BiondVax’s Strategic Research Collaboration: Significant Progress Towards Development Of Innovative Nanosized Antibodies (NanoAbs) for Therapeutic Indications in Addition...

Details:

The collaboration aims to generate and develop NanoAbs with the potential to answering needs underserved by currently approved conventional monoclonal antibody therapeutics as the NanoAbs exhibit potential for patient convenience, safety, and clinical outcomes, at lower costs.

Lead Product(s): Alpaca‑derived Nanosized Antibody

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Max Planck Institute for Multidisciplinary Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 20, 2022

ASK
US

Upload
your Pipeline Activity

Sequence Bio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sequence Bio Announces Discovery Collaboration Agreement with LEO Pharma

Details:

LEO Pharma will leverage insights generated under this collaboration to build robust evidence in support of new potential approaches that significantly impact dermatologic conditions.

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Leo Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 07, 2022

ASK
US

Upload
your Pipeline Activity

Revel Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Details:

The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase).

Lead Product(s): Enzyme Therapy

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Kizoo Technology Capital

Deal Size: $8.4 million Upfront Cash: Undisclosed

Deal Type: Financing March 17, 2022

ASK
US

Upload
your Pipeline Activity

Evommune

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline

Details:

The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound is a PKCtheta inhibitor.

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Andera Partners

Deal Size: $83.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing September 09, 2021

ASK
US

Upload
your Pipeline Activity

Eligo Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million

Details:

Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.

Lead Product(s): EB005

Therapeutic Area: Dermatology Product Name: EB005

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: GSK

Deal Size: $224.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 11, 2021

ASK
US

Upload
your Pipeline Activity

Almirall

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines

Details:

The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: University of Dundee

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 08, 2020

ASK
US

Upload
your Pipeline Activity

Leo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma

Details:

Open Innovation Agreement with LEO Pharma A/S will screen novel VAP-1 inhibitor compounds discovered by Kubota Vision.

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Kubota Vision Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY